The Claim
In adults with obesity, once-weekly subcutaneous semaglutide at a dose of 2.4 mg administered over 68 weeks significantly reduces knee osteoarthritis pain, resulting in a mean improvement of 41.7 points in WOMAC pain scores compared to a 27.5-point improvement with placebo, indicating meaningful symptom relief.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly semaglutide shot helped people with obesity and knee pain from arthritis feel a lot better—much more than those who got a dummy shot.
See the scientific wording
Once-weekly subcutaneous semaglutide at 2.4 mg for 68 weeks significantly reduces knee osteoarthritis pain in adults with obesity, improving WOMAC pain scores by a mean of 41.7 points compared to 27.5 points with placebo, indicating meaningful symptom relief.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
The study gave semaglutide to people with obesity and knee pain and found their pain improved much more than those who got a placebo, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.